glp-1 drugs hypothyroidism Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study GLP-1 Medications Infographic | Medidex

Studies have shown that variations in the GIPR gene are linked to cardiovascular disease and metabolic syndrome characteristics, which supports this idea [110]

How GLP-1 Receptor Agonists Work for Weight Loss GLP-1 receptor agonists function by: Suppressing appetite : They target areas in the brain that control hunger, leading to reduced food intake

Interestingly, it also stimulates insulin secretion from -cells, but with much lower potency than GLP-1 with the mechanism potentially due to the weak binding of glucagon at GLP-1 receptor site [11]

Dual and Triple Agonists: The next generation of medications, such as Tirzepatide (which targets both GLP-1 and GIP receptors), are already demonstrating even greater efficacy for weight loss and blood sugar control

Novos once-daily oral Wegovy is under Food and Drug Administration review with a decision expected later this year, while Lillys orforglipron is set for regulatory submission by the end of the year and a potential launch in 2026